Exane Asset Management Cytom X Therapeutics, Inc. Transaction History

Exane Asset Management

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 21, 2021	SELL	$6.6 - $9.0 $201,748 - $275,112	-30,568 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$6.47 - $7.9 $215,140 - $262,690	-33,252 Reduced 52.1%	30,568 $200,000
Q3 2020 Oct 15, 2020	SELL	$6.55 - $8.83 $157,566 - $212,414	-24,056 Reduced 27.37%	63,820 $424 Million
Q4 2019 Feb 03, 2020	BUY	$5.17 - $8.91 $174,802 - $301,256	33,811 Added 62.54%	87,876 $730,000
Q3 2019 Oct 24, 2019	SELL	$7.38 - $12.25 $390,660 - $648,453	-52,935 Reduced 49.47%	54,065 $398,000
Q2 2019 Aug 05, 2019	BUY	$9.35 - $11.41 $65,450 - $79,870	7,000 Added 7.0%	107,000 $0
Q1 2019 May 07, 2019	BUY	$9.5 - $19.16 $475,000 - $958,000	50,000 Added 100.0%	100,000 $0
Q4 2018 Feb 05, 2019	BUY	$12.69 - $18.61 $280,449 - $411,281	22,100 Added 79.21%	50,000 $755,000
Q3 2018 Nov 16, 2018	BUY	$18.04 - $26.41 $102,828 - $150,537	5,700 Added 25.68%	27,900 $0
Q2 2018 Sep 06, 2018	BUY	$21.38 - $29.68 $89,796 - $124,656	4,200 Added 23.33%	22,200 $0
Q1 2018 Apr 30, 2018	BUY	$21.76 - $34.22 $195,840 - $307,980	9,000 Added 100.0%	18,000 $0
Q4 2017 Feb 08, 2018	BUY	$19.0 - $23.09 $171,000 - $207,810	9,000	9,000 $0

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $70.6M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.